Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine
6th Oct 2021

Cadila Healthcare has received permission from the Drug Controller General of India (DCGI) for conducting phase III trials for its two-dose COVID-19 vaccine ZyCoV-D. The company has already received the emergency use authorization (EUA) from the DCGI for ZyCoV-D to be administered in three doses on August 20, 2021.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.